Intégrale

Integrale Therapeutics is a Paris-based biotechnology company specializing in advanced cell engineering to develop next-generation cell therapies. The company's proprietary STITCH (Selective Targeting and Integration of Transgenes for Cell Engineering) platform allows for the precise and efficient integration of large DNA sequences into the genome, enabling the creation of complex, multi-functional therapeutic cells. This technology aims to overcome current limitations in cell therapy, such as payload size and integration site control, particularly for induced pluripotent stem cell (iPSC) applications. Based in Paris, Integrale is a spin-off from the Institut Pasteur and the Imagine Institute, supported by leading life science investors including Sofinnova Partners. The company's approach is designed to address high-unmet-need areas in oncology and rare genetic diseases.